Squarepoint
NBIX icon

Squarepoint’s Neurocrine Biosciences NBIX Stock Holding History

Squarepoint’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$823K Buy
+5,800
New +$932K ﹤0.01% 2937

Other funds holding NBIX

JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $61B AUM 26.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Squarepoint's NBIX Position: Q3 2026 in Review

Squarepoint reduced its Neurocrine Biosciences (NBIX) stake by 28% in Q3 2026, selling an estimated $2M and leaving 31,684 shares worth $4.49M. The position accounts for ﹤0.01% of the portfolio, ranked #1531.

Squarepoint first reported a position in NBIX in Q4 2015 and has held it in 37 quarters since. The position peaked at $64.3M in Q1 2026. 533 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Squarepoint held 31,684 shares of Neurocrine Biosciences worth $4.49M as of Q3 2026.
  • Squarepoint sold 12,459 Neurocrine Biosciences shares in Q3 2026, an estimated $2M.
  • Neurocrine Biosciences made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #1531 holding.
  • Squarepoint first reported a position in Neurocrine Biosciences in Q4 2015 and has held it in 37 quarters since.
  • Squarepoint's Neurocrine Biosciences position peaked at $64.3M in Q1 2026.
  • 533 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.